ASTHMA/ALLERGY

Cost Studies 

PAA1

CLINICAL EFFECTIVENESS OF ADJUSTABLE DOSING SINGLE INHALER BUDESONIDE/FORMOTEROL FOR ASTHMA AND BUDGET IMPACT ANALYSIS

Kaczor M, Becla L, Wojcik R, Dardzinski W, Walczak J, Nogas G

Arcana Institute, Cracow, Poland

PAA2

EFFECT OF SUBLINGUAL IMMUNOTHERAPY (SLIT) ON DIRECT MEDICAL COSTS FOR PATIENTS WITH ALLERGIC RHINITIS AND ASTHMA: RESULTS FROM THE SIMAP DATABASE STUDY

Berto P¹, Bassi M², Cadario G³, Cantarutti L⁴, Contiguglia R⁵, Crivellaro M⁶, Di Gioacchino M⁷, Frati F⁸, Magazzů C⁵, Marengo F³, Scamarcia A⁴, Schiappoli M⁶, Valle C⁹, Verna N⁷, Giaquinto C¹⁰

¹Pbe consulting, Verona, Italy, ²Rho Hospital, Cerchiate di Pero (MI), Italy, ³Azienda Ospedaliera S.Giovanni Battista di Torino (Molinette), Torino, Italy, ⁴SOSEPE, Padova, Italy, ⁵AUSL 5, Messina, Italy, ⁶Azienda Ospedaliera Verona, Verona, Italy, ⁷D'Annunzio University, Chieti, Italy, ⁸Stallergenes Italy, Milano, Italy, ⁹Ospedale San Paolo, Milano, Italy, ¹⁰University of Padova, Padova, Veneto, Italy

PAA3

COST OF MANAGING ASTHMA EXACERBATIONS WITH STABLE DOSING OF SALMETEROL/FLUTICASONE COMBINED PRODUCT (SFC) COMPARED WITH ADJUSTABLE MAINTENANCE DOSING (AMD) OF FORMOTEROL/ BUDESONIDE COMBINED PRODUCT (FBC) IN POLAND

Orlewska E¹, Cel M², Glogowski C²

¹Centrum Farmakoekonomiki, Warsaw, Poland, ²GSK Commercial Sp. z o.o, Warsaw, Poland

PAA4

PHARMACOECONOMIC ANALYSIS OF USE OF A SIMBICORT TURBUHALER AND SERETIDE MULTIDISK OF ASTHMA PATIENTS

Kulikov A, Lomakin A, Krysanov I, Polivanov V

Moscow Medical Academy, Moscow, Russia

PAA5

ECONOMIC EVALUATION OF A NEW AIRWAY INFLAMMATION MONITOR IN THE DIAGNOSIS AND MANAGEMENT OF ASTHMA IN GERMANY

Berg J¹, Lindgren P¹, Jönsson B²

¹Stockholm Health Economics, Stockholm, Sweden, ²Stockholm School of Economics, Stockholm, Sweden

PAA6

VALUING REDUCED RATES OF OROPHARYNGEAL ADVERSE EVENTS: COMPARISON OF CICLESONIDE WITH FLUTICASONE PROPIONATE

Wlodarczyk JH¹, Harvey C², Caeser M³

¹John Wlodarczyk Consulting Services, New Lambton, NSW, Australia, ²Altana Pharma Pty Ltd, NOrth Ryde, NSW, Australia, ³ALTANA Pharma AG, Konstanz, Germany

PAA7

ANALYZING THE INFLUENCE OF SWITCHING BETWEEN DIFFERENT ASTHMA REGIMES ON MEDICATION ADHERENCE TO ASTHMA THERAPY, RESOURCE UTILIZATION AND COSTS

Buesch K¹, Welte R², Singer C²

¹GSF-National Research Center for Environment and Health, Neuherberg, Bavaria, Germany, ²GlaxoSmithKline, Munich, Germany

PAA8

A COMPARISON OF CLAIMS RATIO BETWEEN PRIMARY AND SECONDARY DRUGS IN THE MANAGEMENT OF ASTHMA. A CANADIAN ANALYSIS

Ciobanu A

AstraZeneca, Mississauga, ON, Canada

Health Care Use & Policy Studies

PAA9

THE EFFECTS OF GENERIC-ONLY DRUG COVERAGE ON INHALED CORTICOSTEROID EXPENDITURES AND USE

Fung V¹, Fireman B¹, Brand R², Newhouse JP³, Hsu J¹

¹Kaiser Permanete, Oakland, CA, USA, ²University of California at San Francisco, San Francisco, CA, USA, ³Harvard University, Boston, MA, USA

PAA10

HEALTH PLAN STRUCTURE AND EXPENDITURES FOR ASTHMA CARE

Nurmagambetov T, Atherly A, Williams S, Redd S

Centers for Disease Control and Prevention, Atlanta, GA, USA

Methods & Concepts

PAA11

COST-EFFECTIVENESS ANALYSIS FOR THE ASSESSMENT OF PREVENTIVE SCHEMES BASED ON GENETIC SCREENING

Gutierrez de Mesa E¹, Hidalgo I¹, Christidis P¹, Ciscar JC¹, Vegas E², Ibarreta D¹

¹Institute for Prospective Technological Studies, JRC-European Commission, seville, Spain, Spain, ²Servicio Madrleńo de Salud, Alcala de Henares. MADRID, Spain

Patient Reported Outcomes 

PAA12

THE EFFECT OF SWITCHING ON ADHERENCE TO DIFFERENT TYPES OF ASTHMA TREATMENT

Buesch K¹, Singer C², Welte R²

¹GSF-National Research Center for Environment and Health, Neuherberg, Bavaria, Germany, ²GlaxoSmithKline, Munich, Germany

PAA13

OBTAINING POPULATION REFERENCE VALUES FOR THE ESPRINT-15 QUESTIONNAIRE, A SPECIFIC QUALITY OF LIFE SCALE FOR ALLERGIC RHINITIS (AR)

Valero A¹, Monclús L², Baro E³, on behalf of Esprint Study Investigators -⁴

¹Hospital Clínic i Provincial de Barcelona, Barcelona, Spain, ²J. Uriach & Cia, S.A, Palau-solitŕ i plegamans, Barcelona, Spain, ³3D Health Research, Barcelona, Spain, ⁴Esprint Study Investigators, Spain, Spain

PAA14

PATIENT-PERCEIVED SIDE EFFECTS OF CICLESONIDE AS COMPARED TO FLUTICASONE PROPIONATE IN THE TREATMENT OF MODERATE ASTHMA USING THE INHALED CORTICOSTEROID QUESTIONNAIRE

van der Molen T¹, Leichtl S², Caeser M²

¹University of Groningen, Groningen, The Netherlands, ²ALTANA Pharma AG, Konstanz, Germany

PAA15

THE CONSTRUCT VALIDITY AND TEST-RETEST RELIABILITY OF THE INHALED CORTICOSTEROID QUESTIONNAIRE (ICQ): A PATIENT SELF-REPORTED SIDE EFFECT SCALE

Foster JM¹, Van Sonderen E¹, Lee AJ², Sanderman R¹, Van der Molen T¹

¹University of Groningen, Groningen, The Netherlands, ²University of Aberdeen, Aberdeen, UK

CARDIOVASCULAR

Clinical Outcomes Studies

PCV1

CLINICAL IMPACT OF DIAGNOSTIC IMAGING OF LOWER EXTREMITY PERIPHERAL VASCULAR DISEASE

Scranton R¹, Dhingra R¹, Lawler E², Hay JW³, Yucel K², Guo A⁴, Balzer T⁴, Gaziano J¹

¹VA Boston Healthcare System, Harvard Medical School, Boston, MA, USA, ²VA Boston Healthcare System, Boston, MA, USA, ³University of Southern California, Los Angeles, CA, USA, ⁴Berlex Laboratories, Wayne, NJ, USA

PCV2

CARDIOVASCULAR RISK FACTORS IN ACUTE CORONARY SYNDROME PATIENTS UNDERGOING PERCUTANEOUS CORONARY INTERVENTION IN 5 EUROPEAN COUNTRIES

McCollam PL¹, Nasuti P², Bae JP¹, Smith H²

¹Eli Lilly and Company, Indianapolis, IN, USA, ²IMS Hospital Group Ltd, Sittingbourne, UK

PCV3

DO WE FOLLOW THE GUIDELINES ON PREVENTION OF CARDIOVASCULAR DISEASE IN OUT-PATIENT CARE ?

Pietrasik A¹, Starczewska M¹, Glowczynska R¹, Opolski G¹, Filipiak KJ¹, Jakubczyk M², Niewada M¹, Latek M³

¹Medical University of Warsaw, Warsaw, Poland, ²Warsaw School of Economics, Warsaw, Poland, ³Warsaw School of Economics, Warszawa, Poland

PCV4

META-ANALYSIS OF THE DIAGNOSTIC ACCURACY OF PRESSURE MEASUREMENTS IN CORONARY ARTERY DISEASE

Bornschein B¹, Klauss V², Siebert U¹

¹UMIT University of Health Sciences, Medical Informatics, and Technology, Hall i. T, Austria, ²University of Munich, Munich, Germany

PCV5

DRUG-ELUTING STENT USE IS ASSOCIATED WITH SIGNIFICANT IMPROVEMENTS IN LONG-TERM CLINICAL OUTCOMES

Eisenstein EL, Tuttle RH, Shaw LK, Anstrom KJ, Kong DF

Duke Clinical Research Institute, Durham, NC, USA

PCV6

REACHING SIGN CHOLESTEROL TARGETS AND BEYOND: RETROSPECTIVE AUDIT OF TARGETS ACHIEVED THROUGH USE OF ROSUVASTATIN IN A SCOTTISH GENERAL PRACTICE

Burnett GR¹, Dickson K¹, Emmas CE²

¹Princes Street Surgery, Thurso, Scotland, UK, ²AstraZeneca UK, Luton, UK

PCV7

REACHING AWMSG TARGETS AND BEYOND-A RETROSPECTIVE AUDIT OF TARGETS ACHIEVED THROUGH USE OF ROSUVASTATIN IN WELSH GENERAL PRACTICE

Moore RP¹, Chapman JR¹, Davies EJ¹, Davies SH¹, Davies N¹, Harfoot DA¹, Emmas CE²

¹Towers Surgery, Barry, Wales, UK, ²AstraZeneca UK, Luton, UK

PCV8

THE EFFECTIVENESS OF ROSUVASTATIN COMPARED WITH OTHER STATINS – RESULTS FROM A ROUTINE CLINICAL PRACTICE SETTING IN THE UK

Hirsch MW¹, O'Donnell JC¹, Jansen JP²

¹AstraZeneca Ltd, Macclesfield, Cheshire, UK, ²Mapi Values, Houten, The Netherlands

PCV9

NON-PERSISTENT USE OF ANTIHYPERTENSIVE DRUGS LEADS TO INCREASED RISK OF HOSPITALIZATIONS FOR ACUTE MYOCARDIAL INFARCTION OR STROKE

Breekveldt-Postma NS¹, Siiskonen SJ¹, Penning-van Beest FJ¹, Falvey H², Vincze G², Erkens JA¹, Herings RM¹

¹PHARMO Institute for Drug Outcomes Research, Utrecht, The Netherlands, ²Novartis Pharma AG, Basel, Switzerland

PCV10

COST-EFFECTIVENESS OF A LIFESTYLE INTERVENTION FOR HYPERTENSION: AN OPEN RANDOMISED CONTROLLED TRIAL

Martikainen JA¹, Kastarinen M², Puska P³, Nissinen A³

¹Centre for Pharmaceutical Policy and Economics (CEPPE), Department of Social Pharmacy, University of Kuopio, Kuopio, Finland, ²Kuopio University Hospital, PL 1777, Kuopio, Finland, ³National Public Health Institute, 00300, Helsinki, Finland

PCV11

CLINICAL EFFECTIVENESS OF BETALOC ZOC COMPARED TO METOPROLOL TARTRATE OR CARVEDILOL IN HYPERTENSION TREATMENT.

Kawalec P¹, Borek E²

¹Jagiellonian University, Kraków, Poland, ²Astra Zeneca Poland, Warsaw, Poland

PCV12

Withdrawn

PCV13

EFFECT OF ABSOLUTE REDUCTION IN LDL CHOLESTEROL ON CARDIOVASCULAR EVENTS: DOES FINAL LDL CHOLESTEROL ACHEIVED MATTER?

Rahilly CR¹, Gaziano J², Scranton R²

¹Boston VA Healthcare System, Jamaica Plain, MA, USA, ²VA Boston Healthcare System, Harvard Medical School, Boston, MA, USA

PCV14

ASCOT-LIKE PATIENT PREVALENCE AMONG THE HYPERTENSIVES IN SPAIN

Sicras A¹, F Bobadilla J², Moreno R³, Arístegui R², García M⁴

¹Badalona Servicios Asistenciales, Barcelona, Spain, ²Pfizer Spain, Alcobendas, Madrid, Spain, ³Hospital Clinico San Carlos, Madrid, Madrid, Spain, ⁴Euroclin Institute, Alcobendas, Madrid, Spain

PCV15

ANALYSIS OF PRESCRIBING PATTERNS OF ANTIHYPERTENSIVE AGENTS (AA) BEFORE AND AFTER PUBLICATION OF THE ANTIHYPERTENSIVE AND LIPID-LOWERING TREATMENT TO PREVENT HEART ATTACK TRIAL (ALLHAT)

Brixner D¹, Maio V²

¹The University of Utah College of Pharmacy, Salt Lake City, UT, USA, ²Thomas Jefferson University, Philadelphia, PA, USA

PCV16

MAIN CARDIOVASCULAR RISK FACTORS: ASSOCIATION AND CONTROL IN A PRIMARY HEALTHCARE SETTING

Sicras A¹, Navarro R¹, Rejas J², F Bobadilla J², García M³, González P²

¹Badalona Servicios Asistenciales, Badalona, Barcelona, Spain, ²Pfizer Spain, Alcobendas, Madrid, Spain, ³Euroclin Institute, Alcobendas, Madrid, Spain

PCV17

PROJECTED IMPACT ON CORONARY HEART DISEASE OF ADDING PROLONGED-RELEASE NICOTINIC ACID (NIASPAN^®) TO STATIN TREATMENT IN EUROPEAN PATIENTS WITH TYPE 2 DIABETES

Liens D¹, Palmer AJ², Valentine WJ², Renaudin C¹, Roze S²

¹Merck Santé, Lyon, France, ²CORE - Center for Outcomes Research, A Unit of IMS, Allschwil, Switzerland

PCV18

OUTCOME OF THIAZOLIDINEDIONE USE IN DISCHARGED DIABETIC PATIENTS WHO WERE HOSPITALIZED FOR HEART FAILURE

Chou HY¹, Huang WF², Tsai YW³

¹National Yang-Ming University, Taipei City, Taiwan, ²National Yang-Ming University, Taipei, Taiwan, ³National Health Research Institutes, Zhunan Town, Miaoli County, Taiwan

PCV19

DISCONTINUED USE OF MYCOPHENOLATE MOFETIL AND GRAFT LOSS IN HEART TRANSPLANT RECIPIENTS

Legorreta AP¹, Kang N² , Gilmore AS², Marehbian J², Naujoks C³ , Machnicki G³

¹UCLA School of Public Health, Los Angeles, CA, USA, ²Health Benchmarks, Inc, Woodland Hills, CA, USA, ³Novartis Pharma AG, Basel, Switzerland

Cost Studies

PCV20

FINANCIAL IMPACT OF EPLERENONE USE IN A SPANISH REFERENCE HOSPITAL

F Bobadilla J¹, García M²

¹Pfizer Spain, Alcobendas, Madrid, Spain, ²Euroclin Institute, Alcobendas, Madrid, Spain

PCV21

ANTIHYPERTENSIVE DRUG BUDGET IMPACT OF THE ANGIOTENSIN II RECEPTOR BLOCKERS (ARB) IN THE UK

Blak BT¹, Weir MR¹, Simoni-Wastila L¹, Shaya FT¹, Cooke CE², Mullins CD¹

¹University of Maryland, Baltimore, MD, USA, ²Pfizer Inc, Ellicott City, MD, USA

PCV22

COST IMPACT OF DIAGNOSTIC IMAGING FOR LOWER EXTREMITY PERIPHERAL VASCULAR DISEASE (PVD)

Hay JW¹, Scranton R², Yucel K³, Guo A⁴, Balzer T⁴, Gaziano J²

¹University of Southern California, Los Angeles, CA, USA, ²VA Boston Healthcare System, Harvard Medical School, Boston, MA, USA, ³VA Boston Healthcare System, Boston, MA, USA, ⁴Berlex Laboratories, Wayne, NJ, USA

PCV23

ECONOMIC BURDEN OF CONTRAST-INDUCED NEPHROPATHY (CIN): IMPLICATIONS FOR PREVENTION STRATEGIES

Subramanian S¹, Bapat B², Zyczynski T³, Tumlin J⁴

¹RTI International, Waltham, MA, USA, ²RTI Interntional, Research Triangle Park, NC, USA, ³GE Healthcare, Princeton, NJ, USA, ⁴University of NC and Southeast Renal Associates, Charlotte, NC, USA

PCV24

CARDIOVASCULAR EVENTS REDUCTION AND COST-EFFECTIVENESS OF ATORVASTATIN VERSUS PRAVASTATIN IN SPANISH POPULATION WITH ACUTE CORONARY SYNDROME (ACS)

F Bobadilla J¹, Checa JC¹, Soto J¹, García M², Martínez E¹, Hernández G¹

¹Pfizer Spain, Alcobendas, Madrid, Spain, ²Euroclin Institute, Alcobendas, Madrid, Spain

PCV25

COST-EFFECTIVENESS OF CLOPIDOGREL IN MEXICO: WITHIN TRIAL ANALYSIS

Jerjes-Sanchez C¹, Trujillo A², Ramos MA³, Hernandez I⁴, Alvarado R⁵, Cruz A⁶, Rangel FJ⁶, Morales E⁷

¹Hospital de Enfermedades Cardiovasculares y Torax-IMSS, Monterrey, Nuevo León, Mexico, ²Hospital General de Zona 57, Tlalnepantla, Mexico, Mexico, ³UMAE CM La Raza, Mexico City, Mexico City, Mexico, ⁴Hospital Juarez de Mexico, Mexico City, Mexico, Mexico, ⁵ISSSTE Durango, Durango, Durango, Mexico, ⁶Hospital PEMEX-Norte, Mexico City, Mexico City, Mexico, ⁷Cardiometabolic Research Unit, Aguascalientes, Aguascalientes, Mexico

PCV26

COST-EFFECTIVENESS OF CLOPIDOGREL IN MEXICO: A LONG TERM ANALYSIS

Jerjes-Sanchez C¹, Trujillo A², Ramos MA³, Hernandez I⁴, Alvarado R⁵, Cruz A⁶, Rangel FJ⁶, Morales E⁷

¹Hospital de Enfermedades Cardiovasculares y Torax-IMSS, Monterrey, Nuevo León, Mexico, ²Hospital General de Zona 57, Tlalnepantla, Mexico, Mexico, ³UMAE CM La Raza, Mexico City, Mexico, ⁴Hospital Juarez de Mexico, Mexico City, Mexico, ⁵ISSSTE Durango, Durango, Mexico, ⁶Hospital PEMEX-Norte, Mexico City, Mexico, ⁷Cardiometabolic Research Unit, Aguascalientes, Mexico

PCV27

COST-EFFECTIVENESS OF BETALOC COMPARED TO CARVEDILOL IN CARDIAC INSUFFICIENCY AND ARTERIAL HYPERTENSION TREATMENT IN POLAND

Kawalec P¹, Borek E²

¹Jagiellonian University, Kraków, Poland, ²Astra Zeneca Poland, Warsaw, Poland

PCV28

COST-EFFECTIVENESS OF INTENSIVE LIPID-LOWERING TREATMENT IN SECONDARY CARDIOVASCULAR PREVENTION IN SPAIN AND GERMANY

Taylor DC¹, Pandya A¹, Thompson D¹, Chu P¹, Graff J², LaRosa JC³, Grundy SM⁴, Wenger NK⁵, Shepherd J⁶, Drummond MF⁷

¹i3 Innovus, Medford, MA, USA, ²Pfizer, Inc, New York, NY, USA, ³State University of New York Health Science Center, Brooklyn, NY, USA, ⁴University of Texas, Dallas, TX, USA, ⁵Emory University School of Medicine, Atlanta, GA, USA, ⁶University of Glasgow, Glasgow, Scotland, UK, ⁷University of York, York, Heslington, UK

PCV29

COST-EFFECTIVENESS ANALYSIS OF ROSUVASTATIN IN TREATING PATIENTS TO LDL-C ATP III GOALS. A MEXICAN PERSPECTIVE OF THE STELLAR TRIAL.

Soto H¹, Mino D², Polanco AC¹, Gomez G³, Miller P⁴

¹Astra Zeneca, Naucalpan, Estado de México, Mexico, ²Instituto Mexicano de Seguro Social, México D.F, México, Mexico, ³Hospital General Dr. Manuel Gea Gonzalez, México D.F, México D.F, Mexico, ⁴Astra Zeneca, Alderley Park, Alderley Park, UK

PCV30

COST-EFFECTIVENESS OF ROSUVASTATIN FOR CARDIOVASCULAR PREVENTION IN HIGH-RISK POPULATIONS IN SWEDEN

Jönsson L¹, Ekman M², Karlsson G³, Brun J³

¹European Health Economics, London, UK, ²Stockholm Health Economics, Stockholm, Sweden, ³AstraZeneca, Södertälje, Sweden

PCV31

HEALTH ECONOMIC ASSESSMENT OF RAISING HDL-C WITH PROLONGED-RELEASE NICOTINIC ACID (NIASPAN^®) WHEN ADDED TO STATIN THERAPY IN PATIENTS WITH DYSLIPIDEMIA AND TYPE 2 DIABETES: AN ANALYSIS FOR SWEDEN

Renaudin C¹, Liens D¹, Palmer AJ², Valentine WJ², Berger W³, Roze S²

¹Merck Santé, Lyon, France, ²CORE - Center for Outcomes Research, A Unit of IMS, Allschwil, Switzerland, ³Merck KGaA, Darmstadt, Germany

PCV32

COST-EFFECTIVENESS OF CLOPIDOGREL IN MYOCARDIAL INFARCTION WITH ST-SEGMENT ELEVATION: EUROPEAN MODEL RESULTS BASED ON CLARITY AND COMMIT

Berg J¹, Lindgren P¹, Jönsson B²

¹Stockholm Health Economics, Stockholm, Sweden, ²Stockholm School of Economics, Stockholm, Sweden

PCV33

COST-EFFECTIVENESS MODEL TO EVALUATE MANAGED VENTRICULAR PACING (MVP) IMPLANTED IN A SPANISH AMBULATORY SURGERY PROGRAM

Rodríguez J¹, Caro JJ², Roda J³, Ward A², Xenakis J², Malik F⁴, Bariz H²

¹Medtronic Iberia, Madrid, Spain, ²Caro Research Institute, Concord, MA, USA, ³General Valencia University Hospital, Valencia, Spain, ⁴Medtronic Sarl, Tolochenaz, Laussane, Switzerland

PCV34

A COST-EFFECTIVENESS ANALYSIS OF OLMESARTAN IN THE TREATMENT OF ARTERIAL HYPERTENSION

Lamotte M¹, Annemans L², Van Loy R³, Koch W⁴

¹IMS Health, Brussel, Brabant, Belgium, ²IMS Health, Brussels, Belgium, ³Sankyo Pharma, Louvain-La-Neuve, Brabant, Belgium, ⁴HaaPACS GmbH, Schriesheim, Schriesheim, Germany

PCV35

ESTIMATING LIFETIME COSTS AND LIFE EXPECTANCY ASSOCIATED WITH CARDIOVASCULAR DISEASE IN A SWISS POPULATION WITH AND WITHOUT METABOLIC SYNDROME

Ray J¹, Darioli R², Roze S³, Azoulay M⁴, Bernhardt M⁴, Valentine WJ⁵

¹IMS Health, Allschwil, Basel, Switzerland, ²Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland, ³CORE - Center for Outcomes Research, A Unit of IMS, Allschwil, Switzerland, ⁴sanofi-aventis (suisse) sa, Meyrin, Geneva, Switzerland, ⁵CORE - Center for Outcomes Research, A Unit of IMS, Allschwil, Basel, Switzerland

PCV36

A HEALTH ECONOMIC EVALUATION OF CONCOMITANT SURGICAL ABLATION FOR ATRIAL FIBRILLATION

Lamotte M¹, Annemans L², Siebert M³

¹IMS Health, Brussel, Brabant, Belgium, ²IMS Health, Brussels, Belgium, ³St-Jude Medical, Zaventem, Vlaams Brabant, Belgium

PCV37

COST-EFFECTIVENESS OF LONG-TERM TREATMENT OF HYPERTENSION WITH IRBESARTAN VS. LOSARTAN OR NO TREATMENT IN DENMARK

Knudsen MS¹, Lange M², Dahl E³

¹Muusmann Research & Consulting AS, Copenhagen, Denmark, ²Sanofi-aventis, Hoersholm, Denmark, ³Bristol-Myers Squibb, Lyngby, Denmark

PCV38

COST MINIMIZATION ANALYSIS OF BIVALIRUDIN VERSUS HEPARIN PLUS PLANNED ABXICIMAB IN PATIENTS UNDERGOING PERCUTANEOUS CORONARY INTERVENTION

Cequier Á¹, Morís C², Badia X³, Lara N³

¹Hospital Universitario de Bellvitge. Universidad de Barcelona, Barcelona, Barcelona, Spain, ²Hospital Universitario Central de Asturias, Asturias, Asturias, Spain, ³Health Outcomes Research Europe, Barcelona, Spain

PCV39

PHARMACOLOGICAL TREATMENT OF HYPERTENSION IN PATIENTS WITH TYPE II DIABETES A COST-MINIMIZATION ANALYSIS

Berto P¹, Cremonesi G²

¹Pbe consulting, Verona, Italy, ²Chiesi Farmaceutici, Parma, Italy

PCV40

A COST-EFFECTIVENESS ANALYSIS OF CARDIAC REHABILITATION AFTER PERCUTANEOUS CORONARY INTERVENTIONS

Lamotte M¹, Annemans L², Raskin A³, Hansen D³, Dendale P³

¹IMS Health, Brussel, Brabant, Belgium, ²IMS Health, Brussels, Belgium, ³Virga Jesse Hospital, Hasselt, Limburg, Belgium

PCV41

A COST CONSEQUENCE ANALYSIS OF THE IMPACT OF JBS 2 ON PATIENTS ELIGIBLE FOR STATIN TREATMENT IN SCOTLAND

Shepherd J¹, Kingslake SL²

¹University of Glasgow, Glasgow, Scotland, UK, ²AstraZeneca UK Ltd, Luton, Bedfordshire, UK

PCV42

IMPACT OF VENTRICULAR ARRHYTHMIAS ON HOSPITALIZATION COSTS IN PATIENTS WITH ACUTE MYOCARDIAL INFARCTION (AMI)

Iyer S¹, Ciuryla V¹, Wang PF²

¹Wyeth Research, Collegeville, PA, USA, ²Premier Healthcare Informatics, Charlotte, NC, USA

PCV43

COST ANALYSIS OF TREATMENT WITH NESIRITIDE FOR ACUTE DECOMPENSATED HEART FAILURE IN A BRAZILIAN SETTING

Pereira M¹, Vianna D², Bacaltchuk J³, Duchesne I³

¹Racionale, Sao Paulo, Brazil, ²University of Rio de Janeiro, Rio de Janeiro, Brazil, ³Janssen-Cilag, Sao Paulo, Brazil

PCV44

COMORBIDITIES, COSTS AND THERAPEUTIC GOALS ACHIEVED IN THE SECONDARY PREVENTION OF THE PRIMARY HEALTH CARE

Sicras A¹, Navarro R¹, LLopart López JR¹, F Bobadilla J², García M³, González P²

¹Badalona Servicios Asistenciales, Badalona, Barcelona, Spain, ²Pfizer Spain, Alcobendas, Madrid, Spain, ³Euroclin Institute, Alcobendas, Madrid, Spain

PCV45

COST OF CHRONIC VENOUS INSUFFICIENCY (CVI) IN POLAND

Bartminski W, Faluta T, Czech M, Pachocki R

Servier Polska, Warszawa, woj. mazowieckie, Poland

PCV46

NON-HOSPITAL COSTS AND NUMBER OF CARDIOVASCULAR RISK FACTORS (CVRF) IN SPANISH HIPERTENSIVE PATIENTS.

F Bobadilla J¹, Sicras A², García M³, Soto J¹

¹Pfizer Spain, Alcobendas, Madrid, Spain, ²Badalona Servicios Asistenciales, Badalona, Barcelona, Spain, ³Euroclin Institute, Alcobendas, Madrid, Spain

PCV47

DIRECT MEDICAL COSTS FOR TREATMENT OF MILD TO MODERATE HYPERTENSION IN PATIENTS WITH TYPE II DIABETES

Berto P¹, Cremonesi G²

¹Pbe consulting, Verona, Italy, ²Chiesi Farmaceutici, Parma, Italy

PCV48

MEDICATION USE AND ASSOCIATED ANNUAL COSTS IN PATIENTS AT RISK OF ATHEROTHROMBOSIS: RESULTS FOR GERMANY, SPAIN AND THE UK FROM THE REDUCTION OF ATHEROTHROMBOSIS FOR CONTINUED HEALTH (REACH) REGISTRY

Mahoney EM¹, Wang K¹, Bruggenjurgen B², Bakhai A³

¹New England Research Institutes, Watertown, MA, USA, ²Charite University Medical Center, Berlin, Germany, ³Barnet & Chase Farm NHS Trust, Barnet, UK

PCV49

COST-UTILITY ANALYSIS USING A MARKOV MODEL TO COMPARE PRESCRIPTION STATINS VERSUS POTENTIAL OVER THE COUNTER STATINS IN USA

Gandhi PK¹, McGhan WF², Peterson AM²

¹University of Florida-Gainesville, Gainesville, FL, USA, ²University of the Sciences in Philadelphia, Philadelphia, PA, USA

PCV50

EFFICACY AND SOCIOECONOMIC RELEVANCE OF HAWTHORN EXTRACT (CRATAEGUS) WS® 1442 IN THE TREATMENT OF NYHA II CHF PATIENTS - RESULTS FROM A PROSPECTIVE THREE-YEAR PHARMACOECONOMIC STUDY

Rychlik R¹, Ernen C¹, Daniel D¹, Klapper HG², Habs M²

¹Institute of Empirical Health Economics, Burscheid, NRW, Germany, ²Dr. Willmar Schwabe GmbH & Co. KG, Karlsruhe, Baden-Württember, Germany

PCV51

ECONOMIC EVALUATION OF DIAGNOSTIC STRATEGIES IN PATIENTS WITH SUSPECTED CORONARY ARTERY DISEASE (CAD) IN THE UK

Ratcliffe A¹, Barwell T¹, Chambers MG²

¹Abacus International, BICESTER, OXON, UK, ²GE Healthcare, Buckinghamshire, UK

PCV52

LOSARTAN-BASED VERSUS ATENOLOL-BASED THERAPY IN PATIENTS WITH HYPERTENSION AND LEFT VENTRICULAR HYPERTROPHY: AN ECONOMIC EVALUATION OF THE LOSARTAN INTERVENTION FOR ENDPOINT REDUCTION IN HYPERTENSION (LIFE) STUDY FOR GERMANY

Krobot KJ¹, Carides GW², Wagner A¹, Burke TA³

¹MSD Sharp & Dohme GmbH, Haar, Germany, ²Merck & Co., Inc, Upper Gwynedd, PA, USA, ³Merck & Co., Inc, Whitehouse Station, NJ, USA

PCV53

COST-UTILITY ANALYSIS OF EPROSARTAN COMPARED TO ENALAPRIL AND RAMIPRIL IN THE TREATMENT OF MODERATE TO SEVERE HYPERTENSION IN SWEDEN

Lindgren P¹, Schwander B², Zöllner Y³, Jönsson B⁴

¹Stockholm Health Economics, Stockholm, Sweden, ²Analytica International, Loerrach, Germany, ³Solvay Pharmaceuticals GmbH, Hannover, Germany, ⁴Stockholm School of Economics, Stockholm, Sweden

PCV54

COST-EFFECTIVENESS ANALYSIS OF DIAGNOSTIC METHODS IN THE MANAGEMENT OF PATIENTS WITH SYMPTOMATIC, LOWER LIMB PERIPHERAL ARTERIAL DISEASE.

Aguiar-Ibáńez R¹, Craig D¹, Collins R¹, Cranny G¹, Burch J¹, Wright K¹, Berry E², Gough M³, Kleijnen J⁴, Westwood M¹

¹Centre for Reviews and Dissemination, York, UK, ²EB Imagistics Ltd, Leeds, UK, ³Leeds General Infirmary, Leeds, UK, ⁴Kleijnen Systematic Reviews Ltd, York, UK

PCV55

ECONOMIC EVALUATION OF DRUG ELUTING STENTS: COST-UTILITY ANALYSIS

Bischof M, Briel M, Bucher HC, Nordmann A

University Hospital Basel, Basel, BS, Switzerland

PCV56

ESTIMATION OF THE PRESENCE OF CARDIOVASCULAR EVENTS AND DIRECT COSTS ASSOCIATED WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE IN AN AMBULATORY SETTING

Sicras A¹, Navarro R¹, F Bobadilla J², García M³, Soto J²

¹Badalona Servicios Asistenciales, Badalona, Barcelona, Spain, ²Pfizer Spain, Alcobendas, Madrid, Spain, ³Euroclin Institute, Alcobendas, Madrid, Spain

Health Care Use & Policy Studies

PCV57

COSTS ASSOCIATED WITH DRUG USE IN THE NON-ADHERENCE TO CHOLESTEROL MANAGEMENT GUIDELINES FOR PRIMARY PREVENTION OF CARDIOVASCULAR DISEASE IN AN ELDERLY POPULATION: THE ROTTERDAM STUDY

Gumbs PD¹, Verschuren WMM², Mantel-Teeuwisse AK¹, De Wit GA², Hofman A³, Trienekens PH⁴, Stricker BHC³, De Boer A¹, Klungel OH¹

¹Utrecht University, Utrecht, Utrecht, The Netherlands, ²National Institute for Public Health and the Environment, Bilthoven, The Netherlands, ³Erasmus University, Rotterdam, The Netherlands, ⁴Stichting Trombosedienst en Artsenlaboratorium Rijnmond, Rotterdam, The Netherlands

PCV58

THE ROLE OF ECONOMIC FACTORS IN THERAPEUTIC DECISION MAKING CONCERNING TREATMENT OF CORONARY ARTERY DISEASE IN POLAND

Banasiak W¹, Jaworski R², Czech M², Pachocki R²

¹4th Military Hospital, Wroclaw, Poland, ²Servier Polska, Warsaw, Poland

PCV59

LIPID TESTING AMONG PATIENTS RECEIVING FIRST-EVER STATIN THERAPY IN UK GENERAL PRACTICES

Phatak H¹, Wentworth C², Burke TA³

¹Rutgers University: The State University of New Jersey, Piscataway, NJ, USA, ²Analytic Consulting Solutions, Wakefield, RI, USA, ³Merck & Co., Inc, Whitehouse Station, NJ, USA

PCV60

A CARE MAP FOR CHF IN THE UK

Knight CJ

Heron Evidence Development Ltd, Letchworth, UK

PCV61

INITIAL PHARMACOTHERAPY FOR PATIENTS WITH DYSLIPIDEMIA IN PRIMARY CARE

Luo N¹, Zhao ²Z, Liu GG³

¹National University of Singapore, Singapore, Singapore, ²Eli Lilly, Indianapolis, IN, USA, ³University of North Carolina at Chapel Hill, Chapel Hill, NC, USA

PCV62

DRUG USE EVALUATION OF ROSUVASTATIN IN A HONG KONG PUBLIC HOSPITAL

Lee VWY, Leung PH, Tomlinson B, Lee KK

The Chinese University of Hong Kong, Shatin, Hong Kong, China

PCV63

Withdrawn

PCV64

Withdrawn

PCV65

ECONOMIC APPRAISAL OF THE ANGIOPLASTY PROCEDURES PERFORMED IN 2004 IN A HIGH-VOLUME DIAGNOSTIC AND SURGICAL CARDIOLOGY UNIT

Ponzi P¹, Di Stasi F¹, Manari A², Guiducci V², Giacometti P², Pignatelli G²

¹Medtronic Italia, Sesto San Giovanni (MI), Italy, ²Arcispedale Santa Maria Nuova, Reggio Emilia, Italy

PCV66

THE VALUE OF MYOCARDIAL PERFUSION SCINTIGRAPHY (MPS) IN CORONARY ARTERY DISEASE (CAD): A REVIEW OF THE ECONOMIC LITERATURE SUBMITTED TO THE UK NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE (NICE)

Sidhu MK¹, Scott DA¹, Vale L², Chambers MG³

¹Fourth Hurdle Consulting, London, UK, ²University of Aberdeen, Aberdeen, UK, ³GE Healthcare, Buckinghamshire, UK

PCV67

PROJECTED COST SAVINGS TO THIRD PARTY PAYERS FOR THE YEAR FOLLOWING GENERIC SIMVASTATIN AVAILABILITY IN USA

Gandhi PK¹, McGhan WF², Spooner JJ³, Peterson AM²

¹University of Florida-Gainesville, Gainesville, FL, ²University of the Sciences in Philadelphia, Philadelphia, PA, USA, ³Advanced Concepts Institute, Philadelphia, PA, USA

PCV68

CLOPIDOGREL PATTERNS OF USE IN ACUTE CORONARY SYNDROME PATIENTS UNDERGOING PERCUTANEOUS CORONARY INTERVENTION IN 5 EUROPEAN COUNTRIES

Smith H¹, McCollam PL², Nasuti P¹, Bae JP²

¹IMS Hospital Group Ltd, Sittingbourne, UK, ²Eli Lilly and Company, Indianapolis, IN, USA

PCV69

RETROSPECTIVE STUDY OF CLOPIDOGREL USE AMONG PATIENTS WITH ACUTE CORONARY SYNDROME (ACS) UNDERGOING CORONARY ARTERY BYPASS GRAFT

Hauch O¹, Doyle J², Stern L², Berenson K², Hendlish S²

¹AstraZeneca, Wilmington, DE, USA, ²Analytica International, New York, NY, USA

PCV70

MANAGEMENT AND OUTCOMES IN THE CARE OF ATRIAL FIBRILLATION IN GERMANY (MOCA)

Bruggenjurgen B¹, McBride D², Willich SN¹

¹Charite University Medical Center, Berlin, Germany, ²Institute for Social Medicine, Epidemiology and Health Economics, Berlin, Germany

PCV71

PHARMACOECONOMIC ANALYSIS OF TREATMENT OF HYPERTENSION IN CLINICAL CENTER OF SERBIA- PHARMACY AND MEDICAL SUPPLY

Simic G

Clinical Center of Serbia, Belgrade, Serbia and Montenegro

Methods & Concepts

PCV72

ANGIOTENSIN II RECEPTOR BLOCKERS (ARBS) FOR MILD TO MODERATE HYPERTENSION: A LITERATURE REVIEW

Maniadakis N¹, Theodoratou T², Fragoulakis V³, Hatzikou M²

¹University hospital of Heraklion, Drosia, Greece, ²Boehringer Ingelheim Ellas, Elliniko, Greece, ³IOVE, Athens, Greece

PCV73

ANALYSIS OF COST AND EFFECTIVENESS DATA USING RANDOM PERMUTATION METHODS

Kolm P

Christiana Care Health System, Newark, DE, USA

PCV74

COST-EFFECTIVENESS ANALYSIS IN CORONARY ARTERY DISEASE DIAGNOSIS: CHOOSING BETWEEN LABORATORY MARKERS

Bogavac-Stanojevic N¹, Ivanova Petrova G², Jelic-Ivanovic Z¹

¹University School of Pharmacy, Belgrade, Serbia, Serbia and Montenegro, ²Medical University, Sofia, Bulgaria, Bulgaria

PCV75

DERIVING COST INPUT VALUES FOR USE IN A MARKOV MODEL FOR EXPLORING THE CLINICAL CONSEQUENCES OF RIMONABANT IN ADDITION TO DIET AND EXERCISE IN OVERWEIGHT OR OBESE SUBJECTS

McEwan P¹, Nicholls C², Caro JJ³

¹Cardiff Research Consortium, Cardiff, UK, ²Sanofi-Aventis, Guildford, Surrey, UK, ³Caro Research Institute, Concord, MA, USA

PCV76

THE GERMAN CARDIOMETABOLIC COST DATABASE - A METHODOLOGICAL APPROACH TO ASSESS COST DATA FOR MODELLING COST-EFFECTIVENESS OF TREATMENT REGIMES FOR PATIENTS WITH MULTIPLE CARDIOMETABOLIC RISK FACTORS.

Fuchs SM¹, Klauss V², Dieterle C², Wasem J³, Aidelsburger P¹

¹Carem GmbH, Sauerlach, Germany, ²University of Munich, Munich, Germany, ³University of Duisburg-Essen, Essen, Germany

PCV77

DISCRETE-EVENT-SIMULATION AN APPROACH THAT CHALLENGES TRADITIONAL MODELING METHODS? AN ILLUSTRATION USING DRUG-ELUTING STENTS

Jahn B¹, Theurl E², Goeree RA³, Bowen J³, Blackhouse G³, Hopkins R³, Tarride JE³

¹Innsbruck Medical University, Innsbruck, Austria, ²Leopold-Franzens-University Innsbruck, Innsbruck, Austria, ³McMaster University, Hamilton, ON, Canada

PCV78

TOWARDS A MODELLED ECONOMIC EVALUATION TO IDENTIFY THE OPTIMAL POPULATION FOR SCREENING OF CORONARY ARTERY DISEASE

Tilden D¹, Pascoe K¹, Higashi MK², Marelli C³, Kennedy L³, Scheijbeler H¹, Aristides M¹

¹IMS, London, UK, ²GE Healthcare, Wauwatosa, WI, USA, ³GE Healthcare, Buckinghamshire, UK

PCV79

CLASSIFYING PATIENTS WITH DYSLIPIDEMIA: A LATENT CLASS ANALYSIS

Liu GG¹, Luo N², Zhao Z³

¹University of North Carolina at Chapel Hill, Chapel Hill, NC, USA, ²National University of Singapore, Singapore, Singapore, ³Eli Lilly, Indianapolis, IN, USA

PCV80

DERIVING UTITLITY VALUES FOR USE IN A MARKOV MODEL FOR EXPLORING THE CLINICAL CONSEQUENCES OF RIMONABANT IN ADDITION TO DIET AND EXERCISE IN OVERWEIGHT OR OBESE SUBJECTS

McEwan P¹, Nicholls C², Getsios D³, Caro JJ³

¹Cardiff Research Consortium, Cardiff, UK, ²Sanofi-Aventis, Guildford Surrey, UK, ³Caro Research Institute, Concord, MA, USA

PCV81

VALIDATION OF THE MODE OF ADMINISTRATION OF THE MEDICATION COMPLIANCE QUESTIONNAIRE

Rosa K¹, Fitzgerald KA¹, Moller RA²

¹Mapi Values USA LLC, Boston, MA, USA, ²Pfizer, New York, NY, USA

PCV82

VALIDATION OF A MODEL TO PREDICT LIFETIME CLINICAL AND ECONOMIC BENEFIT OF RAISING HDL-C IN STATIN-TREATED PATIENTS WITH PERSISTENTLY LOW HDL-C

Renaudin C¹, Berger W², Liens D¹, Valentine WJ³, Palmer AJ³, Roze S³

¹Merck Santé, Lyon, France, ²Merck KGaA, Darmstadt, Germany, ³CORE - Center for Outcomes Research, A Unit of IMS, Allschwil, Switzerland

Patient Reported Outcomes

PCV83

COMPLIANCE PATTERN OF PHARMACOLOGICAL REGIMENS IN HYPERTENSIVES AND/OR DYSLIPIDEMIC PATIENTS IN AMBULATORY CARE IN A SPANISH POPULATION

Sicras A¹, Navarro R¹, F Bobadilla J², García M³

¹Badalona Servicios Asistenciales, Barcelona, Spain, ²Pfizer Spain, Madrid, Spain, ³Euroclin Institute, Alcobendas, Madrid, Spain

PCV84

COMPLIANCE IMPROVEMENTS AND HDL CHOLESTEROL LEVELS IN HYPERTENSIVE PATIENTS IN SPAIN

Sicras A¹, F Bobadilla J², García M³

¹Badalona Servicios Asistenciales, Barcelona, Spain, ²Pfizer Spain, Madrid, Spain, ³Euroclin Institute, Madrid, Spain

PCV85

COMPLIANCE AND PERSISTENCE OF FIXED DOSE VERSUS FREE DOSE COMBINATION THERAPY WITH VALSARTAN AND HCTZ FOR PATIENTS WITH HYPERTENSION

Jackson KC¹, Brixner D², Oderda GM³, Oberg B¹, Sheng X¹, Keskinaslan A⁴

¹University of Utah Health Sciences Center, Salt Lake City, UT, USA, ²The University of Utah College of Pharmacy, Salt Lake City, UT, USA, ³University of Utah, Salt Lake City, UT, USA, ⁴Novartis Pharma, AG, Basel, Switzerland

PCV86

CHARACTERIZATION OF HYPERTENSIVE PATIENTS WHO MIGHT BENEFIT FROM A COMBINATION OF TWO DRUGS IN ONE PILL FOR REDUCTION OF CARDIOVASCULAR RISK

Sturkenboom MC¹, Van der Hoeven Borgman M², Van Kints A², Moller RA³, Fitzgerald K⁴, Rosa K⁵, Cramer JA⁶

¹Erasmus University Medical Center, Soest, The Netherlands, ²Erasmus University Medical Center, Rotterdam, The Netherlands, ³Pfizer, New York, NY, USA, ⁴Mapi Values, Boston, MA, USA, ⁵Mapi Values USA LLC, Boston, MA, USA, ⁶Yale University School of Medicine, West Haven, CT, USA

PCV87

COMPARING COMPLIANCE AND PERSISTENCE RATES FOR HYPERTENSION, DYSLIPIDEMIA, AND DIABETES MEDICATIONS

Cramer JA¹, Benedict A², Muszbek N³, Keskinaslan A⁴, Khan ZM⁵

¹Yale University School of Medicine, West Haven, CT, USA, ²UnitedBiosource Corporation, Budapest, Hungary, ³UnitedBiosource Corporation, London, UK, ⁴Novartis Pharma AG, Basel, Switzerland, ⁵Novartis Pharmaceuticals, East Hanover, NJ, USA

PCV88

MEDICATION TREATMENT PATTERNS FOR DYSLIPIDEMIA IN US

Zhao Z¹, Liu GG², Luo N³

¹Eli Lilly, Indianapolis, IN, USA, ²University of North Carolina at Chapel Hill, Chapel Hill, NC, USA, ³National University of Singapore, Singapore, Singapore

PCV89

THE RELATIONSHIP BETWEEN PATIENT BELIEFS AND ADHERENCE TO CHOLESTEROL-LOWERING MEDICATIONS: IMPLICATIONS FOR DISEASE MANAGEMENT PROGRAMS

Hansen LG¹, Foley K²

¹Thomson Medstat, Northwood, NH, USA, ²Thomson Medstat, Philadelphia, PA, USA

PCV90

DEVELOPMENT OF A NEW MEASURE FOR ASSESSING HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH ATRIAL FIBRILLATION: 'AF-QOL'

Arribas F¹, Ormaetxe JM², Peinado R³, Llorens MÁ⁴, Perulero N⁵

¹Hospital 12 de Octubre, Madrid, Spain, ²Hospital de Basurto, Bilbao, Spain, ³Hospital La Paz, Madrid, Spain, ⁴3M Healthcare, Madrid, Spain, ⁵Health Outcomes Research Europe, Barcelona, Spain

PCV91

PSICOMETRIC PROPERTIES OF THE TREATMENT SATISFACTION WITH MEDICINES QUESTIONNAIRE (SATMED-Q) IN HIPERTENSIVE PATIENTS

Ruíz M¹, Pardo A¹, Sanz de Burgoa V², Rejas J², Soto J², Suárez C³

¹Universidad Autónoma de Madrid, Madrid, Spain, ²Pfizer Spain, Madrid, Spain, ³Hospital de La Princesa, Madrid, Spain

EYE

Clinical Outcomes Studies

PEY1

USE OF BAYESIAN NETWORKS TO SPECIFY THE NOCTURNAL INTRA-OCULAR PRESSURE PEAK FROM DAYTIME MEASUREMENTS IN GLAUCOMA PATIENTS

Nordmann JP¹, Berdeaux G²

¹Centre Hospitalier National des Quinze-Vingts, Paris, France, ²Alcon France, Rueil-Malmaison, France

PEY2

EFFECTIVENESS OF TRAVOPROST VERSUS DORZOLAMIDE + TIMOLOL FIXED COMBINATION IN FIRST LINE TREATMENT OF GLAUCOMA: ANALYZED FROM THE UK GENERAL PRACTITIONER RESEARCH DATABASE

Berdeaux G¹, Lafuma A², Guelfucci F³

¹Alcon France, Rueil-Malmaison, France, ²Cemka-Eval, Bourd-la-Reine, France, ³Cemka-Eval, Bourg-la-Reine, France

PEY3

POSTERIOR CAPSULAR OPACIFICATION AND ND: YAG LASER TREATMENT AFTER CATARACT SURGERY IN FRANCE: COMPARISON ACCORDING TO INTRAOCULAR LENS WITH SQUARE EDGED OPTIC DESIGN

Mimaud V¹, Lafuma A², Koshnood B³, Berdeaux G⁴

¹Cemka, Bourg-la-Reine, France, ²Cemka-Eval, Bourd-la-Reine, France, ³Cemka-Eval, Bourg-la-Reine, France, ⁴Alcon France, Rueil-Malmaison, France

PEY4

EFFECTIVENESS OF BRIMONIDINE VERSUS BRINZOLAMIDE IN TREATMENT OF GLAUCOMA: AN ANALYSIS CONDUCTED ON THE UNITED-KINGDOM GENERAL PRACTITIONER RESEARCH DATABASE

Berdeaux G¹, Lafuma A², Guelfucci F³

¹Alcon France, Rueil-Malmaison, France, ²Cemka-Eval, Bourd-la-Reine, France, ³Cemka-Eval, Bourg-la-Reine, France

PEY5

COMPARISON OF PHYSICIAN AND PATIENT REPORTED OUTCOMES OF ADULTS WITH DRY EYE DISEASE (KERATOCONJUNCTIVITIS SICCA) MANAGED OVER TIME IN A PATIENT REGISTRY

Steeds CS¹, Buchholz P², Irwin DE³, Figueiredo FC⁴, Figueiredo MS⁴

¹CS Consulting, Motherwell, Scoland, UK, ²Allergan Europe, Ettlingen, Germany, ³University of North Carolina, Chapel Hill, NC, USA, ⁴Royal Victoria Infirmary, Tyne and Wear, UK

PEY6

INCIDENCE OF POSTERIOR CAPSULAR OPACIFICATION AND ND: YAG LASER TREATMENT AFTER CATARACT SURGERY IN FRANCE: COMPARISON ACCORDING TO INTRAOCULAR LENS WITH SQUARE EDGED OPTIC DESIGN

Smith AF¹, Boureau C², Lafuma A³, Mimaud V⁴, Somlay K⁵

¹Alcon Laboratories Ltd, Hemel Hempstead, Herts, UK, ²Ophthalmologist, Paris, France, ³Cemka-Eval, Bourd-la-Reine, France, ⁴Cemka, Bourg-la-Reine, France, ⁵Laboratoires Alcon, Rueil Malmaison, France

Cost Studies

PEY7

MODELLING THE HEALTH ECONOMIC IMPACT OF OLOPATADINE COMPARED TO BRANDED AND GENERIC SODIUM CROMOGLYCATE IN THE TREATMENT OF SEASONAL ALLERGIC CONJUNCTIVITIS IN THE UK

Smith AF¹, Clegg J², Guest JF²

¹Alcon Laboratories Ltd, Hemel Hempstead, Herts, UK, ²Catalyst Health Economics Consultants, Northwood, Middlesex, UK

PEY8

WHEN IS IT COST-EFFECTIVE TO TREAT OCULAR HYPERTENSION? RESULTS OF A DECISION-ANALYTIC HEALTH ECONOMIC MODEL

Stewart WC¹, Stewart JA¹, Nassar Q¹, Mychaskiw MA²

¹Pharmaceutical Research Network, LLC, Charleston, SC, USA, ²Pfizer Inc, New York, NY, USA

PEY9

ASSESSMENT OF THE COST-EFFECTIVENESS OF TRAVOPROST VERSUS LATANOPROST, AS SINGLE AGENTS FOR GLAUCOMA TREATMENT IN FRANCE

Payet S¹, Berdeaux G², Launois R¹

¹REES, Paris, France, ²Alcon France, Rueil-Malmaison, France

PEY10

COST-EFFECTIVENESS OF TWO TREATMENT SEQUENCES IN GLAUCOMA TREATMENT: XALATAN®-XALACOM® VERSUS TRAVATAN®-DUOTRAV®

Maurel F¹, Le pen C¹, Berdeaux G²

¹Aremis, Neuilly sur Seine, France, ²Alcon France, Rueil-Malmaison, France

PEY11

MODELING THE COST AND CONSEQUENCES OF RESTOR®, A MULTIFOCAL INTRAOCULAR LENS (IOL) IN REFRACTIVE SURGERY IN FRANCE

Berdeaux G¹, Lafuma A², Guelfucci F³

¹Alcon France, Rueil-Malmaison, France, ²Cemka-Eval, Bourd-la-Reine, France, ³Cemka-Eval, Bourg-la-Reine, France

PEY12

MODELING THE COSTS AND CONSEQUENCES OF RESTOR®, A MULTIFOCAL INTRAOCULAR LENS (IOL), AFTER CATARACT SURGERY IN FRANCE

Berdeaux G¹, Lafuma A², Guelfucci F³

¹Alcon France, Rueil-Malmaison, France, ²Cemka-Eval, Bourd-la-Reine, France, ³Cemka-Eval, Bourg-la-Reine, France

PEY13

LAST STAGE GLAUCOMA IN EUROPE: COSTS AND QUALITY OF LIFE OF PATIENTS FROM 4 COUNTRIES

Aagren M¹, Arnavielle S², Bron A², Thygesen J³, Baggesen K⁴, Azuara-Blanco A⁵, Neville S⁵, Buchholz P⁶

¹MUUSMANN Research & Consulting, Copenhagen, Denmark, ²University Hospital Dijon, Dijon, France, ³Rigshospitalet, Copenhagen, Denmark, ⁴County of Northern Jutland, Aalborg SV, Denmark, ⁵Aberdeen University Hospital, Aberdeen, Scotland, UK, ⁶Allergan Europe, Ettlingen, Germany

PEY14

BIMATOPROST, LATANOPROST, AND TRAVOPROST FOR THE TREATMENT OF GLAUCOMA: A COST-EFFECTIVENESS ANALYSIS IN SCANDINAVIA USING A DECISION-ANALYTIC HEALTH ECONOMIC MODEL

Stewart WC¹, Stewart JA¹, Passmore CL¹, Mychaskiw MA²

¹Pharmaceutical Research Network, LLC, Charleston, SC, USA, ²Pfizer Inc, New York, NY, USA

PEY15

LATANOPROST VERSUS TIMOLOL MONOTHERAPY FOR THE TREATMENT OF GLAUCOMA: A COST-EFFECTIVNESS ANALYSIS IN SCANDINAVIA AND THE UK USING A DECISION-ANALYTIC HEALTH ECONOMIC MODEL

Stewart WC¹, Stewart JA¹, Mychaskiw MA²

¹Pharmaceutical Research Network, LLC, Charleston, SC, USA, ²Pfizer Inc, New York, NY, USA

PEY16

COST-UTILITY ANALYSIS FOR PEGAPTANIB IN AGE-RELATED MACULAR DEGENERATION IN THE UK: THE IMPACT OF DEMOGRAPHIC AND DISEASE CHARACTERISTICS

Wolowacz S¹, Roskell N², Maciver F¹, Kelly S³

¹RTI-Health Solutions, Manchester, Manchester, UK, ²RTi Health Solutions, Manchester, UK, ³Pfizer, Tadworth, Surrey, UK

PEY17

COST-EFFECTIVENESS OF PEGAPTANIB IN AGE-RELATED MACULAR DEGENERATION: IMPACT OF DIFFERENCES BETWEEN US AND UK HEALTH CARE SYSTEMS

Javitt J¹, Wolowacz S², Roskell N², Maciver S², Kelly S³, Pleil A⁴, Zlateva G⁵

¹Johns Hopkins School of Medicine, Washington, DC, USA, ²RTI-Health Solutions, Manchester, UK, ³Pfizer, Tadworth, Surrey, UK, ⁴Pfizer Inc, San Diego, CA, USA, ⁵Pfizer Inc, New York, NY, USA

Health Care Use & Policy Studies

PEY18

CHANGES IN MEDICAL AND SURGICAL TREATMENTS OF GLAUCOMA BETWEEN 1997 AND 2003 IN FRANCE

Baudouin C¹, Renard JP², Bron A³, Denis P⁴, Nordmann JP⁵, Sellem E⁶, Kenigsberg PA⁷, Levrat F⁸, Solesse De Gendre A⁸, Rouland JF⁹

¹Centre Hospitalier National des Quinze Vingts, PARIS, France, ²Hôpital d’Instruction des Armées du Val de Grâce, Paris, France, ³Hôpital Général, Dijon, France, ⁴Hôpital Edouard Herriot, Lyon, France, ⁵Centre Hospitalier National des Quinze-Vingts, Paris, France, ⁶Centre Ophtalmologique Kleber, Lyon, France, ⁷PAK Santé, France, Paris, France, ⁸Pfizer, Paris, France, ⁹Hôpital Huriez, Lille, France

PEY19

PROSTAGLANDIN AGONIST USE WITH AND WITHOUT ADJUNCTIVE THERAPY FOR THE TREATMENT OF GLAUCOMA: A CANADIAN POPULATION BASED ANALYSIS

Iskedjian M¹, Walker J², Desjardins O³, Covert D⁴, Einarson TR⁵

¹PharmIdeas USA Inc, Concord, NC, USA, ²Brock University, Faculty of Business, St-Catherines, ON, Canada, ³PharmIdeas Research and Consulting Inc, Oakville, ON, Canada, ⁴Alcon Research Ltd, Forth Worth, TX, USA, ⁵University of Toronto, Toronto, ON, Canada

Methods & Concepts

PEY20

MEASURING CURRENT USE OF OCULAR HYPOTENSIVE THERAPIES: ACCOUNTING FOR RESTART RATES

Schwartz GF¹, Platt R², Reardon G³, Mychaskiw MA⁴

¹Glaucoma Consultants, Greater Baltimore Medical Center; Wilmer Eye Institute, Johns Hopkins University; University of Maryland, Baltimore, MD, USA, ²McGill University, Montreal, QC, Canada, ³Informagenics, LLC, Worthington, OH, USA, ⁴Pfizer Inc, New York, NY, USA

PEY21

IMPACT OF BILATERAL NEOVASCULAR AGE-RELATED MACULAR DEGENERATION AND RELATED VISUAL IMPAIRMENT ON PATIENTS' QUALITY OF LIFE AND FUNCTIONING: A SURVEY OF FIVE COUNTRIES

Xu X¹, Zlateva G², Goss TF¹, Buggage R², Cruess A³

¹Covance Market Access Services, Gaithersburg, MD, USA, ²Pfizer Inc, New York, NY, USA, ³Dalhousie University, Halifax, NS, Canada

Patient Reported Outcomes

PEY22

MEDICATION ADHERENCE AND HEALTH CARE COSTS WITH INTRODUCTION OF LATANOPROST THERAPY FOR GLAUCOMA IN A MEDICARE MANAGED CARE POPULATION

Bhosle MJ¹, Balkrishnan R¹, Reardon G², Anderson RT³

¹The Ohio State University College of Pharmacy, Columbus, OH, USA, ²Informagenics, Worthington, OH, USA, ³Wake Forest University School of Medicine, Winston Salem, NC, USA

PEY23

VISION WITH RESTOR® VERSUS MONOFOCAL INTRAOCULAR LENSES (IOL) AFTER CATARACT SURGERY: RESULTS OF A POOLED ANALYSIS

Berdeaux G¹, Viala M², Arnould B²

¹Alcon France, Rueil-Malmaison, France, ²Mapi Values France, Lyon, France

PEY24

METRIC PROPERTIES OF THE MACDQOL IN FRENCH, GERMAN, ITALIAN, AND AMERICAN POPULATIONS: AN INDIVIDUALISED QOL INSTRUMENT SPECIFIC TO MACULAR DISEASE (MD)

Berdeaux G¹, Mesbah M², Bradley C³

¹Alcon France, Rueil-Malmaison, France, ²Université Pierre et Marie Curie, Paris, France, ³University of London, Egham, UK

PEY25

HEALTH-RELATED QUALITY-OF-LIFE AND UTILITY IN DUTCH GLAUCOMA PATIENTS

Van Gestel A, Schouten JS, Webers CA, Beckers HJ, Schrooten MA, Severens JL, Hendrikse F

Academic Hospital Maastricht, Maastricht, The Netherlands

PEY26

VISION BENEFIT FROM MULTI-FOCAL INTRAOCULAR LENS (IOL) AFTER CATARACT SURGERY ESTIMATED BY PRINCIPAL COMPONENTS ANALYSIS

Berdeaux G¹, Viala M², Arnould B²

¹Alcon France, Rueil-Malmaison, France, ²Mapi Values France, Lyon, France

PEY27

DEVELOPMENT OF A QUESTIONNAIRE ASSESSING PATIENT SATISFACTION WITH EYE DROPS IN OCULAR HYPERTENSION AND GLAUCOMA

Berdeaux G¹, Trudeau E², Vigneux M²

¹Alcon France, Rueil-Malmaison, France, ²Mapi Values, Lyon, France

NEUROLOGICAL DISORDERS

Clinical Outcomes Studies

PND1

META-ANALYSIS OF THE EFFICACY AND TOLERABILITY OF PRAMIPEXOLE AND ROPINIROLE IN RESTLESS LEGS SYNDROME (RLS)

Quilici S¹, Nicolas A², Abrams K³, Martin M¹, Lleu PL⁴, Finnern H⁵

¹i3 Innovus, Uxbridge, Middlesex, UK, ²Centre Hospitalier le Vinatier, Bron Cedex, France, ³University of Leicester, Leicester, UK, ⁴Boehringer Ingelheim France, Reims Cedex, France, ⁵Boehringer Ingelheim GmbH, Ingelheim, Germany

Cost Studies

PND2

ESTIMATING THE BUDGET IMPACT OF LEVETIRACETAM AS ADJUNCTIVE THERAPY IN CHILDREN WITH REFRACTORY PARTIAL ONSET SEIZURE IN THE UK

Heaney D¹, Germe M², Brown M³

¹National Hospital for Neurology and Neurosurgery, London, UK, ²UCB, Braine-l'Alleud, Belgium, ³UCB, Slough, UK

PND3

COST-EFFECTIVENESS ANALYSIS OF ADD-ON THERAPY IN PARTIAL REFRACTORY EPILEPSY IN MEXICO

Constantino-Casas P¹, Garcia-Contreras F¹, Nevarez-Sida A¹, Del Angel-García G², Rojas-Martínez E², García-Constantino M²

¹Mexican Institute of Social Security, México, Distrito Federal, Mexico, ²Instituto Mexicano del Seguro Social, México City, Mexico City, Mexico

PND4

PREGABALIN VS GABAPENTIN IN THE TREATMENT OF NEUROPATHIC PAIN IN ITALY: A COST-EFFECTIVENESS ANALYSIS

Pradelli L¹, Marchettini P², Iannazzo S¹

¹Advanced Research Srl, Turin, Italy, ²Istituto Scientifico San Raffaele, Milano, Italy

PND5

TREATMENT OF EARLY PARKINSONIAN PATIENTS WITH RASAGILINE OR ROPINIROLE. WHAT IS THE MOST COST-EFFECTIVE TREATMENT STRATEGY IN FINLAND?

Armand C¹, Eckert L¹, Yrjönen T²

¹H. Lundbeck A/S, Paris, France, ²Oy H. Lundbeck Ab, Turku, Finland

PND6

RETROSPECTIVE EVALUTION OF THE DOSES OF BOTOX AND DYSPORT IN THE MANAGEMENT OF DYSTONIA - A COST MINIMISATION ANALYSIS

Jenkins D¹, Grünewald R², Dorward B², Girod I³

¹MORPh Consultancy Ltd, Worcester, Worcestershire, UK, ²Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, UK, ³Allergan Limited, Marlow, Bucks, UK

PND7

PREDICTORS OF HEALTH CARE AND NON-HEALTH COSTS IN PATIENTS WITH REFRACTORY EPILEPSY IN SPAIN: FINDINGS FROM THE LINCE STUDY

Rejas J¹, Peńa P², Sancho J³, Rufo M⁴, Palacios G¹, Martínez S⁵, Masramon X⁵

¹Pfizer Spain, Alcobendas, Madrid, Spain, ²Universitary Hospital 12 de Octubre, Madrid, Madrid, Spain, ³General University Hospital, Valencia, Valencia, Spain, ⁴UniversityHospital "Virgen del Rocio", Sevilla, Sevilla, Spain, ⁵European Biometrics Institute, Barcelona, Barcelona, Spain

PND8

COST-EFFECTIVENESS OF TREATING RESTLESS LEGS PATIENTS WITH PRAMIPEXOLE COMPARED TO NO TREATMENT IN SWEDEN

Lees M¹, Roberts G¹, Tabberer M¹, Björkman J², Ulfberg J³, Finnern H⁴

¹Oxford Outcomes Ltd, Oxford, Oxon, UK, ²Boehringer Ingelheim AB, Stockholm, Sweden, ³Inland Hospital, Division Tynset, Tynset, Norway, ⁴Boehringer Ingelheim GmbH, Ingelheim, Germany

PND9

COST UTILITY ANALYSIS OF LEVODOPA-CARBIDOPA VS LEVODOPA-CARBIDOPA-ENTACAPONE IN PARKINSON DISEASE IN MEXICO

Garcia-Contreras F¹, Nevarez-Sida A¹, Constantino-Casas P¹, Rojas-Martínez E², García-Constantino M², Del Angel-García G²

¹Mexican Institute of Social Security, México, Distrito Federal, Mexico, ²Instituto Mexicano del Seguro Social, México City, Mexico City, Mexico

Health Care Use & Policy Studies

PND10

A FUNCTIONAL ANALYSIS OF THE RELATIONSHIP BETWEEN AGE AND MIGRAINE IN THE UNITED STATES OF AMERICA

Victor TW, Barlas S

Endo Pharmaceuticals, Chadds Ford, PA, USA

Methods & Concepts

PND11

MODELING LONG-TERM 'REAL WORLD' OUTCOMES OF DISEASE-MODIFYING THERAPY IN RELAPSING-REMITTING ONSET MULTIPLE SCLEROSIS

Skedgel C¹, Brown MG², Bhan V¹

¹Dalhousie University, Halifax, NS, Canada, ²Capital Health Nova Scotia, Halifax, NS, Canada

PND12

A LITERATURE REVIEW OF PATIENT-REPORTED OUTOMES (PROS), NEUROPSYCHOLOGICAL AND COGNITIVE INSTRUMENTS IN PARKINSON'S DISEASE

Staniek V, Emery MP

Mapi Research Trust, Lyon, France

Patient Reported Outcomes

PND13

PSICOMETRIC PROPERTIES OF THE TREATMENT SATISFACTION WITH MEDICINES QUESTIONNAIRE (SATMED-Q) IN PATIENTS WITH REFRACTORY EPILEPSY

Ruíz M¹, Rejas J², Palacios G², Pardo A¹, Soto J²

¹Universidad Autónoma de Madrid, Madrid, Spain, ²Pfizer Spain, Madrid, Spain

PND14

TREATMENT OF NEUROPATHIC PAIN IN MULTIPLE SCLEROSIS: A POPULATION BASED WILLINGNESS-TO-PAY ANALYSIS

Iskedjian M¹, Piwko C¹, Desjardins O¹, Bereza B¹, Jaszewski B², Einarson TR³

¹PharmIdeas Research and Consulting Inc, Oakville, ON, Canada, ²Bayer Healthcare, Toronto, ON, Canada, ³University of Toronto, Toronto, ON, Canada

PND15

RELAPSING-REMITTING MULTIPLE SCLEROSIS (RR-MS) PATIENTS' VALUATION OF MS TREATMENT BENEFITS

Narewska J¹, Lloyd A¹, Dewilde S², Hass SL³, Miller DW³

¹United BioSource Corporation, London, UK, ²United BioSource Corporation, Brussels, Belgium, ³Elan Pharmaceuticals Inc, San Diego, CA, USA

OSTEOPOROSIS

Clinical Outcomes Studies

POS1

EFFECT OF COMORBIDITIES ON THE EARLY MORTALITY AFTER FEMORAL NECK FRACTURE IN ELDERLY IN HUNGARY

Sebestyén A¹, Boncz I¹, Tóth F², Betlehem J², Nyárády J², Jeges S²

¹National Health Insurance Fund Administration (OEP), Budapest, Hungary, ²University of Pécs, Pécs, Hungary

POS2

LOSS OF TREATMENT BENEFIT DUE TO LOW COMPLIANCE WITH BISPHOSPHONATE THERAPY

Penning-van Beest FJA¹, Van den Boogaard CHA¹, Erkens JA¹, Olson M², Herings RMC¹

¹PHARMO Institute, Utrecht, The Netherlands, ²Novartis Pharma AG, Basel, Switzerland

POS3

KAPLAN-MEIER SURVIVAL ANALYSIS OF PATIENTS WITH MEDIAL AND LATERAL FEMORAL NECK FRACTURE OVER 60

Sebestyén A¹, Boncz I¹, Betlehem J², Nyárády J², Tóth F²

¹National Health Insurance Fund Administration (OEP), Budapest, Hungary, ²University of Pécs, Pécs, Hungary

Cost Studies

POS4

COMPARING THE COST-EFFECTIVENESS OF RHBMP-2 IN THE TREATMENT OF OPEN TIBIA FRACTURES IN GERMANY, FRANCE, AND UK

Chhabra A¹, Bentley A², Oliver E³, Salaun B⁴, Greenberg D⁵, Alt V⁶

¹Medtronic Europe Sarl, Tolochenaz, Switzerland, ²Abacus International, Bicester, UK, ³Medtronic Ltd, Watford, UK, ⁴Medtronic France S.A.S, Boulogne, France, ⁵Ben-Gurion University of the Negev, Beer-Sheva, Israel, ⁶University Hospital Giessen-Marburg , Brackenheim, Germany

POS5

AN ECONOMIC EVALUATION OF ZOLEDRONIC ACID TREATMENT IN PAGET'S DISEASE OF BONE IN THE HUNGARIAN HEALTH CARE SETTING

Kosa J

Novartis Hungary Ltd, Budapest, Pest, Hungary

POS6

ECONOMIC ANALYSIS: IBANDRONATE (BONVIVA®) IV INJECTION FOR THE TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS (PMO) IN THE UK

Cowell W¹, Koay A¹, Hunjan M²

¹Roche Products Ltd, Welwyn Garden City, UK, ²GlaxoSmithkline, Middlesex, UK

POS7

COST-EFFECTIVENESS OF RISEDRONATE VS. GENERIC ALENDRONATE: CONSIDERATION OF CALCIUM SUPPLEMENTS

Moehrke W¹, Pasquale M², Moeller G¹

¹Procter & Gamble Pharmaceuticals, Schwalbach a.Ts, Germany, ²Procter & Gamble Pharmaceuticals, Mason, OH, USA

POS8

THE SOCIETAL BURDEN OF OSTEOPOROSIS

Borgström F

European Health Economics, Stockholm, Sweden

POS9

COMPARISON OF THE BURDEN OF ILLNESS OF DISPLACED AND UNDISPLACED FEMORAL NECK FRACTURE AFTER REDUCTION INTERNAL FIXATION

Sebestyén A¹, Boncz I¹, Tóth F², Fodor B², Betlehem J², Nyárády J²

¹National Health Insurance Fund Administration (OEP), Budapest, Hungary, ²University of Pécs, Pécs, Hungary

Health Care Use & Policy Studies

POS10

OSTEOPOROSIS RELATED HEALTH CARE UTILISATION IN HUNGARY BY THE NATIONWIDE HEALTH INSURANCE DATABASE

Gulácsi L¹, Boncz I², Péntek M³, Falusi Z², Sebestyén A², Tóth E³, Horváth C⁴

¹Corvinus University of Budapest, Budapest, Hungary, ²National Health Insurance Fund Administration, Budapest, Hungary, ³Flor Ferenc County Hospital, Kistarcsa, Hungary, ⁴Semmelweis University, Budapest, Hungary

POS11

EVOLUTION OF THE CONSUMPTION OF BISPHOSPHONATES AND RALOXIFENE FINANCED BY THE SPANISH NATIONAL HEALTH SYSTEM FOR OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN

Gaspar MD

University of Barcelona, Barcelona, Spain

POS12

THE DIFFUSION OF NEW DRUG IN TAIWAN MEDICAL CARE UNDER NATIONAL HEALTH INSURANCE: THE CASE OF COX2

Tsai YW¹, Huang WF², Wen YW³, Chen PF³

¹National Health Research Institutes, Zhunan Town, Taiwan, ²National Yang-Ming University, Taipei, Taiwan, ³National Health Research Institutes, Miaoli County, Taiwan

Methods & Concepts

POS13

THE ESTIMATION OF COST_EFFECTIVENESS THRESHOLDS PRIOR TO THE START OF LARGE CLINICAL STUDIES

Van Staa TP¹, Cooper C², Leufkens HG³

¹General Practice Research Database, London, UK, ²University of Southampton, Southampton, UK, ³Utrecht University, Utrecht, The Netherlands

Patient Reported Outcomes

POS14

QUALITY OF LIFE ACCORDING TO EQ-5D AFTER OSTEOPOROTIC HIP FRACTURE IN POLAND

Golicki D¹, Sliwka A¹, Fijewski G², Latek M³

¹Medical University of Warsaw, Warsaw, Poland, ²Medical University of Warsaw, Department of Orthopaedics and Traumatology of Locomotor System, Warsaw, Poland, ³Warsaw School of Economics, Warszawa, Poland

POS15

CHANGES IN THE HEALTH STATUS AFTER FEMORAL NECK FRACTURE MEASURED BY EQ-5D

Sebestyén A¹, Péntek M², Boncz I¹, Gulácsi L³, Sándor J⁴, Nyárády J⁴

¹National Health Insurance Fund Administration (OEP), Budapest, Hungary, ²Flor Ferenc County Hospital, Kistarcsa, Hungary, ³Corvinus University of Budapest, Budapest, Hungary, ⁴University of Pécs, Pécs, Hungary

POS16

LONG TERM QUALITY OF LIFE RELATED TO OSTEOPOROTIC FRACTURES; 13-18 MONTHS AFTER FRACTURE

Ström O¹, Borgström F², Zethraeus N³, Jönsson B³

¹Stockholm Health Economics, Stockholm, Uppland, Sweden, ²European Health Economics, Stockholm, Sweden, ³Stockholm School of Economics, Stockholm, Uppland, Sweden

POS17

BASELINE CHARACTERISTICS OF FRENCH POSTMENOPAUSAL WOMEN WITH OSTEOPOROSIS IN THE EUROPEAN FORSTEO OBSERVATIONAL STUDY (EFOS)

Rajzbaum G¹, Tcherny S², Liu Leage S², Germa C²

¹Saint Joseph Hospital, Paris, France, ²Lilly France, Suresnes, France

SMOKING

Cost Studies

PSM1

THE HIGH COST OF CIGARETTE SMOKING IN GERMANY IN 2003

Neubauer S¹, Welte R¹, Beiche A², Koenig HH³, Buesch K¹, Leidl R¹

¹GSF-National Research Center for Environment and Health, Neuherberg, Germany, ²General Hospital Laupheim, Laupheim, Germany, ³University of Leipzig, Leipzig, Germany

PSM2

COST-UTILITY ANALYSIS FOR SMOKING CESSATION THERAPY IN JAPAN

Igarashi A¹, Fukuda T¹, Oshima A², Nakamura M³, Tsutani K¹

¹Tokyo University, Tokyo, Japan, ²Osaka Medical Center for Cancer and Cardiovascular Diseases, Osaka, Japan, ³Osaka Medical Center for Health Science and Promotion, Osaka, Japan

URINARY/KIDNEY

Clinical Outcomes Studies

PUK1

FACTORS ASSOCIATED WITH OVERACTIVE BLADDER IN MEN AND WOMEN: RESULTS FROM THE EPIC STUDY

Irwin DE¹, Milsom I², Reilly K³, Hunskaar S⁴, Kopp Z³, Herschorn S⁵, Coyne KS⁶, Kelleher C⁷, Artibani W⁸, Hampel C⁹, Abrams P¹⁰

¹University of North Carolina, North Carolina, NC, USA, ²Sahlgrenska Academy at Goteborg University, Göteborg, Sweden, ³Pfizer, Inc, New York, NY, USA, ⁴University of Bergen, Bergen, Norway, ⁵University of Toronto, Toronto, ON, Canada, ⁶United BioSource Corporation, Bethesda, MD, USA, ⁷St. Thomas' Hospital, London, England, UK, ⁸University of Padova, Padova, Padova, Italy, ⁹Johannes-Gutenberg-Universität, Mainz, Germany, ¹⁰Southmead Hospital, Bristol Urological Institute, Bristol, UK

PUK2

LINKING CNI REGIMEN ADHERENCE TO HOSPITAL DAYS AND HEALTH CARE COSTS

Legorreta AP¹, Gilmore AS², Marehbian J², Naujoks C³, Kilburg A³

¹UCLA School of Public Health, Los Angeles, CA, USA, ²Health Benchmarks, Inc, Woodland Hills, CA, USA, ³Novartis Pharma AG, Basel, Switzerland

Cost Studies

PUK3

BUDGET IMPACT ANALYSIS OF INCLUDING RENAL REPLACEMENT THERAPY IN THE BENEFIT PACKAGE OF UNIVERSAL COVERAGE IN THAILAND

Kasemsup V, Prakongsai P, Tangcharoensathien V

International Health Policy Program - Thailand, Nonthaburi, Thailand

PUK4

AN ECONOMIC EVALUATION OF DE NOVO RENAL TRANSPLANT RECIPIENTS USING BRANDED (B-CSA) VS. NON-BRANDED CYCLOSPORINE MODIFIED (NB-CSA)

Helderman JH¹, Gilmore AS², Ryskina K², Legorreta AP³, Naujoks C⁴, Machnicki G⁴

¹Vanderbilt University, Nashville, TN, USA, ²Health Benchmarks, Inc, Woodland Hills, CA, USA, ³UCLA School of Public Health, Los Angeles, CA, USA, ⁴Novartis Pharma AG, Basel, Switzerland

PUK5

COSTS AND COST-EFFECTIVENESS OF EPOETIN IN PATIENTS WITH CHRONIC RENAL INSUFFICIENCY DURING THE PREDIALYSIS PERIOD IN POLAND

Niewada M¹, Kowalik E², Jakubczyk M³, Rutkowski B⁴, Szkultecka-Debek M⁵

¹Medical University of Warsaw, Warsaw, Poland, ²Institute of Cardiology, Warsaw, Poland, ³Warsaw School of Economics, Warsaw, Poland, ⁴Medical University of Gdansk, Gdansk, Poland, ⁵Roche Polska Sp. z o.o, Warsaw, Poland

PUK6

COST-EFFECTIVENESS OF TREATMENT WITH EPOIETIN ALPHA FOR PATIENTS WITH ANAEMIA DUE TO RENAL FAILURE – THE CASE OF SWEDEN

Glenngĺrd AH¹, Schön S², Persson U³

¹The Swedish Institute for Health Economics, IHE, Lund, Sweden, ²Ryhov County Hospital, Jönköping, Sweden, ³The Swedish Institute for Health conomics, IHE, Lund, Sweden

PUK7

ECONOMIC EVALUATION OF TRANSURETHRAL NEEDLE ABLATION (PROSTIVA®) VS. TRANSURETHRAL RESECTION OF THE PROSTATE (TURP) IN BENIGN PROSTATIC HYPERPLASIA (BPH) IN THE SPANISH SETTING

Serrano D¹, Rodríguez J¹, Darba J², Restovic G², Fernandez E³

¹Medtronic Iberia, Madrid, Spain, ²Universitat de Barcelona, Barcelona, Spain, ³Hospital Ramón y Cajal, Madrid, Spain

PUK8

COST-EFFICACY OF FINASTERIDE, DOXAZOSIN AND THE COMBINATION OF BOTH IN THE TREATMENT OF BENIGN PROSTATIC HYPERPLASIA (BPH) IN FRANCE BASED ON THE MTOPS STUDY

Lafuma A¹, Souchet TP², Briand Y², Guelfucci F³

¹Cemka-Eval, Bourd-la-Reine, France, ²Merck Sharp & Dohme - Chibret, Paris, France, ³Cemka-Eval, Bourg-la-Reine, France

PUK9

COST OF ILLNESS IN ITALIAN WOMEN WITH LUTS FOLLOWED AT UROLOGY CENTRES: THE FLOW STUDY

Sgarbi S¹, Rizzi CA², Santini AM², Prezioso D³, Zattoni F⁴, Pesce F⁵, Scarpa RM⁶, Tubaro A⁷, Artibani W⁸

¹MediData srl, Modena, Italy, ²Boehringer Ingelheim, Milan, Italy, ³University “Federico II”, Naples, Italy, ⁴Policlinico G. Rossi, Verona, Italy, ⁵CPO Hospital Ostia, Roma, Italy, ⁶University of Torino, Turin, Italy, ⁷S. Andrea Hospital, Rome, Italy, ⁸University of Padova, Padova, Italy

PUK10

A COMPARATIVE STUDY OF THE ECONOMIC BURDEN OF OVERACTIVE BLADDER AND URINARY URGE INCONTINENCE ACROSS 6 WESTERN COUNTRIES

Reeves P¹, Irwin DE², Kopp Z³, Bridge S⁴, Milsom I⁵, Kelleher C⁶, Artibani W⁷

¹Fourth Hurdle Consulting Ltd, London, UK, ²University of North Carolina, North Carolina, NC, USA, ³Pfizer, Inc, New York, NY, USA, ⁴Pfizer Ltd, Tadworth, Surrey, UK, ⁵Sahlgrenska University Hospital, Göteborg, Sweden, ⁶Guy's and St Thomas' NHS Trust, London, UK, ⁷University of Padova, Padova, Italy

PUK11

Withdrawn

PUK12

DECISION MODEL OF RESOURCE (TIME) SAVINGS GENERATED BY EXTENDED DOSING OF ERYTHROPOIESIS STIMULATING PROTEIN (ESP) FOR THE TREATMENT OF ANEMIA IN CHRONIC KIDNEY DISEASE (CKD) PATIENTS

Barlev A¹, Young S², Bokhari A³, Roberts K⁴, Globe D¹

¹Amgen, Thousand Oaks, CA, USA, ²Mid-Atlantic Nephrology Associates, PA, Baltimore, MD, USA, ³WNERTA / Baystate Medical Center, Springfield, MA, USA, ⁴Research By Design, LLC, Evergreen Park, IL, USA

Health Care Use & Policy Studie 

PUK13

TRENDS IN MEDICATION PRESCRIPTION FOR ANEMIA MANAGEMENT OF CHRONIC KIDNEY DISEASE IN A NATIONALLY REPRESENTATIVE SAMPLE OF OUTPATIENT SETTINGS IN THE UNITED STATES

Rasu RS¹, Balkrishnan R²

¹University of Missouri Kansas City, Kansas City, MO, USA, ²The Ohio State University College of Pharmacy, Columbus, OH, USA

Methods & Concepts

PUK14

A COST-UTILITY ANALYSIS IN A UK SETTING OF CINACALCET FOR SECONDARY HYPERPARATHYROIDISM IN END STAGE RENAL DISEASE.

Mealing SJ¹, Garside R¹, Pitt M¹, Anderson R¹, D'Sousa R², Stein K¹

¹Peninsula Medical School, Exeter, Devon, England, ²Royal Devon and Exeter Hospital, Exeter, Devon, England

PUK15

MODELLING COST-EFFECTIVENESS USING A DYNAMIC PRICE PATH WITH GENERIC SUBSTITUTION SCENARIOS: COST-EFFECTIVENESS OF CINACALCET IN UK PATIENTS WITH END-STAGE RENAL DISEASE (ESRD) ON HEMODIALYSIS

Maetzel A¹, Cangialose C², Roze S³

¹Amgen (Europe) GmbH / University of Toronto, Zug, Switzerland, ²Amgen Inc, Thousand Oaks, CA, USA, ³CORE - Center for Outcomes Research, A Unit of IMS, Basel, Switzerland

PUK16

COST-EFFECTIVENESS ANALYSIS OF SOLIFENACIN FLEXIBLE DOSING IN PATIENTS WITH OVERACTIVE BLADDER SYMPTOMS IN FOUR NORDIC COUNTRIES

Milsom I¹, Wickstrřm J², Poulsen PB²

¹Sahlgrenska University Hospital, Göteborg, Sweden, ²Muusmann Research & Consulting AS, Kolding, Denmark

PUK17

USE OF SIMULATION TO CAPTURE THE MULTIFACTORIAL ASPECTS OF RENAL DISEASE

Migliaccio-Walle K, Moller J, Huybrechts KF, Caro JJ

Caro Research Institute, Concord, MA, USA

Patient Reported Outcomes

PUK18

A MULTICENTRE STUDY OF RENAL TRANSPLANT PATIENTS USING THE SF-36 AND THE END STAGE RENAL DISEASE SYMPTOM CHECK-LIST (ESRD-SCL)

Ortega T, Ortega F, Valdés C, Rearch Network on Transplantation (FC

Hospital Universitario Central de Asturias, Oviedo, Spain

PUK19

OPEN MULTICENTER STUDY OF HEALTH RE LATED QUALITY OF LIFE BEFORE AND AFTER SOLID ORGAN TRANSPLANTATION (KIDNEY, LIVER, HEART AND LUNG)

Ortega T, Ortega F, Valdés C, Research Network on Transplantation RFC

Hospital Universitario Central de Asturias, Oviedo, Spain

PUK20

PATIENTS UNDER 65 YEARS OF AGE ON RENAL TRANSPLANT WAITING LISTS SHOW A WORSE PERCEIVED STATE OF HEALTH THAN OLDER ONES

Rebollo P¹, Ortega F², Ortega T², Research Network on Transplantation RFC²

¹BAP Health Outcomes, Oviedo, Spain, ²Hospital Universitario Central de Asturias, Oviedo, Spain

PUK21

RESEARCH NETWORK ON TRANSPLANTATION: FEMALES ON THE WAITING LIST FOR RENAL TRANSPLANT SHOW A POORER PERCEIVED STATE OF HEALTH THAN DO MALES

Rebollo P¹, Ortega F², Ortega T², Research Network on Transplantation RFC²

¹BAP Health Outcomes, Oviedo, Asturias, Spain, ²Hospital Universitario Central de Asturias, Oviedo, Asturias, Spain

PUK22

COMPARISON OF THE PRO ENDPOINTS FOUND IN LABELING CLAIMES OF URINARY INCONTINENCE DRUGS WITH THOSE RECOMMENDED BY THE CORRESPONDING EMEA NOTE FOR GUIDANCE

Caron M¹, Emery MP², Acquadro C³, Marquis P⁴, Piault E⁴

¹Mapi Reserach Trust, Lyon, France, ²Mapi Research Trust, Lyon, France, ³Mapi Resaerch Institute, Lyon, France, ⁴MAPI VALUES USA, Boston, MA, USA

PUK23

IMPACT OF OVERACTIVE BLADDER ON FREQUENCY OF SEXUAL ACTIVITY AND SEXUAL SATISFACTION IN WOMEN: RESULTS FROM THE EPIC STUDY

Irwin DE¹, Milsom I², Reilly K³, Hunskaar S⁴, Kopp Z³, Herschorn S⁵, Coyne KS⁶, Kelleher C⁷, Artibani W⁸, Hampel C⁹, Abrams P¹⁰

¹University of North Carolina, North Carolina, NC, USA, ²Sahlgrenska Academy at Goteborg University, Göteborg, Sweden, ³Pfizer, Inc, New York, NY, USA, ⁴University of Bergen, Bergen, Norway, ⁵University of Toronto, Toronto, ON, Canada, ⁶United BioSource Corporation, Bethesda, MD, USA, ⁷St. Thomas' Hospital, London, UK, ⁸University of Padova, Padova, Italy, ⁹Johannes-Gutenberg-Universität, Mainz, Germany, ¹⁰Southmead Hospital, Bristol Urological Institute, Bristol, UK

PUK24

LINGUISTIC VALIDATION OF THE OVERACTIVE BLADDER QUESTIONNAIRE (OAB-Q), OVERACTIVE BLADDER SHORT FORM QUESTIONNAIRE (OAB-Q SF), AND OAB ASSESSMENT TOOL (OAB- V8) IN 4 LANGUAGES

Reilly K¹, McKown S², Gawlicki M³, Coyne KS⁴

¹Pfizer, Inc, New York, NY, USA, ²Corporate Translations, Inc, Chicago, IL, USA, ³Corporate Translations, Inc, East Hartford, CT, USA, ⁴United BioSource Corporation, Bethesda, MD, USA

PUK25

LINGUISTIC VALIDATION OF THE PATIENT PERCEPTION OF BLADDER CONDITION QUESTIONNAIRE (PPBC) IN 10 LANGUAGES

Reilly K¹, McKown S², Gawlicki M³, Coyne KS⁴

¹Pfizer, Inc, New York, NY, USA, ²Corporate Translations, Inc, Chicago, IL, USA, ³Corporate Translations, Inc, East Hartford, CT, USA, ⁴United BioSource Corporation, Bethesda, MD, USA

PUK26

LINGUISTIC VALIDATION OF THE OVERACTIVE BLADDER SATISFACTION QUESTIONNAIRE (OAB-S) IN 13 LANGUAGES

Reilly K¹, McKown S², Gawlicki M³, Piault E⁴

¹Pfizer, Inc, New York, NY, USA, ²Corporate Translations, Inc, Chicago, IL, USA, ³Corporate Translations, Inc, East Hartford, CT, USA, ⁴Mapi Values, Boston, MA, USA

PUK27

RISK OF LEAKAGES IN DAILY ACTIVITIES, RE-WORKING THE CONCEPTUAL FRAMEWORK

Arnould B¹, Bosio-Legoux B², Dard S¹, Bresson S³, Costa P⁴

¹Mapi Values France, Lyon, France, ²Lilly France, Suresnes, France, ³Contractor for Lilly France, Suresnes, France, ⁴Carémeau University Hospital, Nîmes, France

PUK28

VALIDATION OF THE PELVIC ORGAN PROLAPSE/URINARY INCONTINENCE SEXUAL FUNCTION QUESTIONNAIRE IN ITALIAN WOMEN. THE GYNAEFLOW STUDY

Simoni L¹, Lessi P², Artibani W³, Meschia M⁴, Cervigni M⁵, Milani R⁶, Minini G⁷, Riva D⁸, Graziottin A⁹

¹MediData srl, Modena, Italy, ²Boehringer Ingelheim, Milan, Italy, ³University of Padova, Padova, Padova, Italy, ⁴Az. Osp. di Legnano P.O. Magenta - Ostetricia Ginecologia, Magenta, Italy, ⁵Ospedale S. Carlo di Nancy - Ostetricia Ginecologia, Roma, Italy, ⁶Ospedale Bassini - Ostetricia Ginecologia, Milan, Italy, ⁷Az. Osp. Spedali Civili - Struttura Semplice Dipartimentale di Uroginecologia, Brescia, Italy, ⁸Ospedale di Cantů - Ginecologia, Como, Italy, ⁹Istituto S. Raffaele, Milan, Italy